Nama Insights

Insulet (PODD)

Healthcare · Medical Devices · NASDAQ

S&P 500
Insulet (PODD) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $9.52B, a trailing price-to-earnings ratio of 20.7 and a free-cash-flow yield of 3.5%. Over the most recent reported fiscal year, revenue grew 30.7% and free cash flow per share grew 21.4%. Nama's AI scorecard rates it Buy, 7.2 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Buy · 7.2/10
Clearly positive, short of the top band. As of Nov 20, 2026.
Momentum
Trailing · -54.6% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-62.5%
How far the last close sits under the highest price of the past five years.
Market cap$9.52B
Trailing P/E20.7
Price / book6.0
Price / sales3.0
FCF yield3.5%
Dividend yield—
Gross margin71.9%
Operating margin18.4%
Net margin13.4%
Revenue growth (YoY)+30.7%
Revenue growth (3-yr annual)+27.5%
EPS growth (YoY)+49.5%
FCF/share growth (YoY)+21.4%
Beta1.1
ExchangeNASDAQ
SectorHealthcare
IndustryMedical Devices

PODD earnings

Next report: Feb 17, 2027 (Q4 2026, EPS estimate $1.75). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 4, 2026 $1.99 $1.59 +25.2% $842.00M
Q2 2026 Aug 5, 2026 $1.66 $1.45 +14.5% $801.70M
Q1 2026 May 6, 2026 $1.42 $1.19 +19.3% $761.70M
Q4 2025 Feb 18, 2026 $1.55 $1.46 +6.2% $783.80M

PODD analyst price target

Median target $179.00 from 23 analysts, ranging $160.00 – $200.00.

Medical Devices peers

TickerCompanyMarket capP/E
ABT Abbott Laboratories $179.90B 19.3
MDT Medtronic $128.69B 17.6
SYK Stryker $119.19B 21.9
BSX Boston Scientific $62.31B 13.5
EW Edwards Lifesciences $59.73B 35.3
GEHC GE HealthCare Technologies $37.03B 16.7
DXCM DexCom $29.91B 30.0
PHG Koninklijke Philips $28.60B 14.7
Explore live PODD data on Nama Insights →

Recent Congressional trades

Insulet trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Gilbert Cisneros House Buy $1,001 - $15,000 Nov 10, 2026
Gilbert Cisneros House Sell $1,001 - $15,000 Oct 12, 2026
Gilbert Cisneros House Buy $1,001 - $15,000 Sep 10, 2026
Daniel Goldman House Sell $1,001 - $15,000 Aug 13, 2023
Tina Smith Senate Sell $250,001 - $500,000 —
Tina Smith Senate Sell $15,001 - $50,000 —
Tina Smith Senate Sell $250,001 - $500,000 —
Tina Smith Senate Sell $100,001 - $250,000 —
Tina Smith Senate Sell $100,001 - $250,000 —

PODD FAQ

Is PODD a buy?
Nama's AI scorecard currently rates Insulet Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PODD's P/E ratio?
Insulet trades at a trailing price-to-earnings ratio of 20.7.
When does PODD report earnings?
Insulet's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $1.75.
What is the PODD price target?
The median analyst price target from 23 analysts is $179.00, with a range of $160.00 – $200.00.
Is PODD Shariah compliant?
Nama's AAOIFI-style screen reads Insulet as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.